443 related articles for article (PubMed ID: 23089540)
1. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
Li T; Huang S; Dong M; Gui Y; Wu D
Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
3. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.
Gannon PO; Lessard L; Stevens LM; Forest V; Bégin LR; Minner S; Tennstedt P; Schlomm T; Mes-Masson AM; Saad F
Eur J Cancer; 2013 Jul; 49(10):2441-8. PubMed ID: 23541563
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer.
Oh JJ; Hong SK; Byun SS; Choe G; Lee SE
Urol Oncol; 2013 Jul; 31(5):595-600. PubMed ID: 21658977
[TBL] [Abstract][Full Text] [Related]
5. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
[TBL] [Abstract][Full Text] [Related]
6. Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression.
Nouh MA; Wu XX; Okazoe H; Tsunemori H; Haba R; Abou-Zeid AM; Saleem MD; Inui M; Sugimoto M; Aoki J; Kakehi Y
Cancer Sci; 2009 Sep; 100(9):1631-8. PubMed ID: 19549252
[TBL] [Abstract][Full Text] [Related]
7. Expression profile of CD44s, CD44v6, and CD44v10 in localized prostate cancer: effect on prognostic outcomes following radical prostatectomy.
Tei H; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jul; 32(5):694-700. PubMed ID: 24468288
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia.
Nägler DK; Krüger S; Kellner A; Ziomek E; Menard R; Buhtz P; Krams M; Roessner A; Kellner U
Prostate; 2004 Jul; 60(2):109-19. PubMed ID: 15162377
[TBL] [Abstract][Full Text] [Related]
9. Over-expression of small ubiquitin-like modifier proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer.
Mu J; Zuo Y; Yang W; Chen Z; Liu Z; Tu J; Li Y; Yuan Z; Cheng J; He J
Chin Med J (Engl); 2014; 127(23):4060-5. PubMed ID: 25430449
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
11. SUMO-specific protease 1 promotes prostate cancer progression and metastasis.
Wang Q; Xia N; Li T; Xu Y; Zou Y; Zuo Y; Fan Q; Bawa-Khalfe T; Yeh ET; Cheng J
Oncogene; 2013 May; 32(19):2493-8. PubMed ID: 22733136
[TBL] [Abstract][Full Text] [Related]
12. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.
Raatikainen S; Aaltomaa S; Kärjä V; Soini Y
Hum Pathol; 2014 Nov; 45(11):2211-7. PubMed ID: 25175169
[TBL] [Abstract][Full Text] [Related]
13. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
Wang Q; Diao X; Sun J; Chen Z
Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
[TBL] [Abstract][Full Text] [Related]
14. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
16. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
17. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
19. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
[TBL] [Abstract][Full Text] [Related]
20. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
